Search

Displaying results 861 - 870 of 7479 in total
  1. Drug

    Astemizole

    go.drugbank.com/drugs/DB00637
    ApprovedWithdrawn

    It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.

  2. Drug

    Bicalutamide

    go.drugbank.com/drugs/DB01128
    ApprovedInvestigational

    Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers.

    Products: Nu-bicalutamide, Van-bicalutamide
  3. Drug

    Dapagliflozin

    go.drugbank.com/drugs/DB06292
    ApprovedInvestigational

    [A6757] Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents. … [A261601] Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise.

    Mixtures: XIGDUO® XR 10MG/1000MG TABLETAS RECUBIERTAS DE LIBERACION PROLONGADA, XIGDUO® XR 10MG/1000MG TABLETAS RECUBIERTAS DE LIBERACION PROLONGADA
  4. Drug

    Glutamic acid

    go.drugbank.com/drugs/DB00142
    ApprovedInvestigationalNutraceutical

    A peptide that is a homopolymer of glutamic acid.

    Mixtures: SOLUCION DP-AMINE, TRAVASOL PLUS 15% LIBRE DE BISULFITO
  5. Drug

    Infliximab

    go.drugbank.com/drugs/DB00065
    ApprovedInvestigational

    Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. … Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades.

  6. Drug

    Daprodustat

    go.drugbank.com/drugs/DB11682
    ApprovedInvestigational

    Daprodustat is a small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor that was developed by GSK. Patients with CKD cannot induce erythropoietin (EPO) production in response to hypoxia or anemia. As a potent in...

  7. Drug

    Pegaspargase

    go.drugbank.com/drugs/DB00059
    ApprovedInvestigational

    [L44667] Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. … Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia

    Products: ONCASPAR® 750 U/ML POLVO PARA SOLUCIÓN INYECTABLE, ONCASPAR POWDER FOR SOLUTION FOR INJECTION/INFUSION 750 U/ML
  8. Drug

    Voxelotor

    go.drugbank.com/drugs/DB14975
    Approved

    [L10403] and is unique from other drugs used to treat sickle cell anemia, such as [hydroxyurea], [L-glutamine], and [crizanlizumab][A188135,A188138] due to its novel mechanism of action. … Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels.

  9. Drug

    Phentolamine

    go.drugbank.com/drugs/DB00692
    ApprovedInvestigational

    While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral

  10. Drug

    Vosoritide

    go.drugbank.com/drugs/DB11928
    ApprovedInvestigational

    Achondroplasia is an autosomal dominant genetic disease and the most common cause of dwarfism in humans. … [A242273] While the remarkably short half-life of endogenous CNP - 2 to 3 minutes due to its rapid degradation by endopeptidases - makes it ineffective as a therapeutic intervention,[A242273] the development